

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>GAJARIA RAJAN</u> (Last) (First) (Middle) <u>C/O CORTEVA, INC.</u> <u>974 CENTRE ROAD, CRP 735</u> (Street) <u>WILMINGTON DE</u> <u>19805</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>06/01/2019</u>	3. Issuer Name and Ticker or Trading Symbol <u>Corteva, Inc. [CTVA]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>See Remarks</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>47,065.7714⁽¹⁾</u>	<u>D</u>	
<u>Common Stock</u>	<u>32⁽²⁾</u>	<u>I</u>	<u>Held in 401(k) plan</u>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Non-Qualified Stock Options⁽³⁾</u>	<u>(4)</u>	<u>02/14/2024</u>	<u>Common Stock</u>	<u>7,129</u>	<u>27.27</u>	<u>D</u>	
<u>Non-Qualified Stock Options⁽³⁾</u>	<u>(4)</u>	<u>02/13/2025</u>	<u>Common Stock</u>	<u>5,760</u>	<u>28.86</u>	<u>D</u>	
<u>Non-Qualified Stock Options⁽³⁾</u>	<u>(4)</u>	<u>02/12/2026</u>	<u>Common Stock</u>	<u>18,317</u>	<u>26.86</u>	<u>D</u>	
<u>Non-Qualified Stock Options⁽³⁾</u>	<u>(5)</u>	<u>02/10/2027</u>	<u>Common Stock</u>	<u>13,897</u>	<u>35.72</u>	<u>D</u>	
<u>Non-Qualified Stock Options⁽³⁾</u>	<u>(6)</u>	<u>02/15/2028</u>	<u>Common Stock</u>	<u>5,393</u>	<u>41.94</u>	<u>D</u>	

Explanation of Responses:

- On June 1, 2019, the Reporting Person received a dividend of one (1) share of Corteva, Inc. common stock for every three (3) shares of DowDuPont Inc. held by the Reporting Person, and the Reporting Person's equity awards denominated in DowDuPont common stock were adjusted, in part, into equity awards denominated in Corteva common stock, all as described in Corteva's Registration Statement on Form 10 filed with the Securities and Exchange Commission on May 6, 2019. This amount includes restricted stock units and related dividend equivalent units.
- On June 1, 2019, the Reporting Person received a dividend of one (1) share of Corteva, Inc. common stock for every three (3) shares of DowDuPont Inc. held by the Reporting Person, all as described in Corteva's Registration Statement on Form 10 filed with the Securities and Exchange Commission on May 6, 2019.
- In connection with the separation, certain outstanding DowDuPont stock options were converted into awards of options to purchase shares of the Issuer's common stock. The number of shares and exercise prices of each option award were adjusted in a manner intended to preserve the economic/intrinsic value of the original DowDuPont stock option.
- This option is fully vested and exercisable.
- 9,264 options are vested and exercisable. The remaining options will vest on February 10, 2020.
- 1,797 options are vested and exercisable. The remaining options will vest in two equal installments on February 15, 2020 and February 15, 2021.

Remarks:

Executive Vice President, Business Platforms

/s/Robert Hahm, attorney-in-
fact 06/10/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Cornel Fuerer, Robert Hahm and Abigail Jarrell, or either of them acting singly and with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Corteva, Inc. (the "Company"), Forms 3, 4, and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended the "Exchange Act"), and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the "SEC") and any securities exchange or similar authority, including without limitation the execution and filing of a Form ID or any other documents necessary or appropriate to obtain codes and passwords to enable the undersigned to file the Forms 3, 4 and 5 electronically with the SEC; and
- (3) take any other action in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by or for, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this power of attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever required, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request and on behalf of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with any provision of Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of this 26th day of April, 2019.

Signed and acknowledged:

/s/ Rajan Gajaria

Rajan Gajaria